For people living with osteoporosis, making decisions about treatment can
sometimes feel overwhelming. There are different types of medications,
different ways they are given, and new treatment options continue to become
available. One term patients may increasingly hear from their doctors,
pharmacists, or health plans is "biosimilar." But what exactly is a
biosimilar? Is it the same medication? Does it work the same way? Is it as
safe? And what should a patient know if their doctor or insurance company
recommends switching from a biologic medication they are already taking to
a biosimilar? This episode approaches those questions from the patient
perspective. Sally Fullman helps guide the conversation by asking the kinds
of questions patients may have when they encounter biosimilars as part of
their osteoporosis care. Answering those questions is Dr. Naga Yalla, an
endocrinologist and Associate Professor of Medicine at Washington
University School of Medicine.
More episodes from "Bone Talk"
Don't miss an episode of “Bone Talk” and subscribe to it in the GetPodcast app.
